Interim data on Spineart’s Baguera-C cervical disc shows the device meets the threshold for a non-inferiority claim compared to a study control, the medtech company said March 11.
Spineart plans to submit premarket approval for the disc in August, according to a news release. The disc’s nucleus can move in all six degrees of freedom with independent angular rotations and independent translational motions.
The investigational device exemption trial is assessing the Baguera-C disc for single-level disc replacement compared to the Mobi-C disc for symptomatic cervical disease. It spans 25 U.S. sites and includes 285 patients.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
